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Role of Splenectomy in Human Liver 
Transplantation Under Modern-Day 
Immunosuppression 
FAROKH SAMIMI, MD, WILLIAM D. IRISH, MSc, BIJAN EGHTESAD, MD, 
ANTHONY J. DEMETRIS, MD, THOMAS E. STARZL, MD, PhD, 
and JOHN J. FUNG, MD, PhD 
Between January 1987 and October 1991, 1466 patients underwent consecutive Orthotopic 
Liver Transplantation (OLTx) at the University of Pittsburgh. Forty of these patient's had 
concomitant splenectomy with OLTx. These patients were compared to 147 randomly 
selected OLTx patients without splenectomy within the same time period. One-year patient 
and graft survival (PS and GS) were lower in splenectomized (Splx) patients compared to 
nonsplenectomized (non-Splx) patients (59% vs 86% PS, 55% vs 80% GS, respectively). 
One-month and one-year patient mortality in the Splx group was higher than in the non-splx 
patients (20% vs 3.4%, P < 0.001 for one month; 40% vs 14.3%, P = 0.003 for one year, 
respectively). One-month and one-year sepsis-related mortality was also high in Splx patients 
(17.5% vs 2.7%, P = 0.0022, for one month, and 30% vs 11.5%, P = 0.0043, for one year, 
respectively). We conclude that concomitant splenectomy with OLTx has a significantly 
higher patient mortality mainly due to its septic complications and, at present, unless there is 
a specific indication for a splenectomy, the routine addition of this procedure to liver allograft 
surgery would not be recommended. 
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There are contradictory reports regarding the effect 
of splenectomy on allograft rejection following trans-
plantation (1-14). Some have reported a beneficial 
effect of splenectomy either pre- or peritransplanta-
tion (1-4,6, 7, 9, 10) and have attributed this benefit 
to a reduction in antibody production (I, 2) or im-
proved leukocyte count and therefore tolerance to 
azathioprine (AZA) (3, 4, 6, 10, 15). Others have 
shown no benefit, discouraging the routine use of this 
procedure because of its potentially lethal complica-
tions due to delayed infection and thromboembolic 
events (5, 8, 13, 16). 
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Because of the nearly universal presence of pan-
cytopenia in seriously ill liver candidates and con-
sequent problems with AZA dosing, concomitant 
splenectomy was performed with liver transplanta-
tion in most hepatic recipients until 1980. With the 
advent of non myelotoxic agents, such as cyclospor-
ine. the routine use of this frequently difficult ad-
juvant procedure was discontinued and is rarely 
performed today. 
The objective of our study was to examine the role 
of splenectomy in liver transplantation and to identify 
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TABLE 1. RECIPIENT CHARAcrERISTICS 
Splenectomized Nonsplenectomized 
N (%) N (%) P 
Number 40 147 
Age (mean:!: SD) 44.9 :!: 10.3 45.4 :!: 11.7 0.810 
Sex 
Male 22 (55.0) 90 (61.2) 0.476 
Female 18 (45.0) 57 (38.8) 
Etiology of liver disease 
Viral 9 (22.5) 25 (17.0) 0.497 
Tumors 5 (12.5) 14 (9.5) 
Biliarv 10 (25.0) 29 ( 19.7) 
Othe;s 16 (40.0) 79 (53.7) 
Positive lymphocytotoxic 
cross-match • 10/38 (26.3) 23/144 (16.0) 0.141 
Immunosuppression 
Azathioprine 13 (32.5) 35 (23.8) 0.265 
Cyclosporine 26 (65.0) 69 ( 46.9) 0.128 
FK506 13 (32.5) 72 (49.0) 
Rescue FK506 1 (2.5) 6 (4.1) 
Prednisone 40 (100.0) 146 (99.3) 1.000 
PRAt 
0% 23 (63.9) 98 (69.5) 0.083 
0-29% 4 (11.1) 27 (19.1) 
2:30% 9 (25.0) 16 ( 11.3) 
RBC transfusion (mean 
:!: so) 
Total 43.5 :!: 38.3 23.8 :!: 26.0 0.001 
Intraoperative 28.6:!: 29.1 18.2 :!: 22.1 0.017 
Perioperative 14.7 :t 21.3 5.5 :!: 7.0 0.008 
Platelet count (mean :!: 
so) 
Preoperative 133.2 :!: 83.6 138.0 :!: 102.4 0.850 
Postoperative 292.2 :!: 254.7 257.1 :!: 139.8 0.784 
UNOS status:!: 
1 and 2 7 (20.0) 33 (23.6) 0.789 
3 13 (37.1) 46 (32.9) 
4 6 (17.1 ) 32 (22.9) 
4US 9 (25.7) 29 (20.7) 
• Lymphocytotoxic cross-match status was not available in five patients: two SpJx. 
three controls. 
t PRA was unknown in 10 patients: four SpJx. six controls. 
;j: UNOS status was unknown in 12 patients: five SpJx. seven controls. 
the potential hazards associated with this procedure 
in modern immunosuppressive regimens. 
MATERIALS AND METHODS 
The records of 1466 patients who underwent OLTx at the 
University of Pittsburgh between January 1987 and October 
1991 were reviewed. Nineteen patients undergoing upper 
abdominal exenteration and thirteen patients WIth splenec-
tomy (Splx) following OLTx were excluded from this study. 
From the remaining 1434 patients. we identified 40 (2.8%) 
who had undergone combined OLTx + Splx. The course of 
these patients was compared to 150 randomly selected 
non-Splx patients from the same transplant period. The 
sample size was calculated to ensure that a 25% or more 
difference in mortality could be detected between the Splx 
and the non-Splx group using methods of unequal group 
sizes (17). The records of three patients clluld not he 
obtained. therefore. the remaining 147 patients served as 
1932 
the non-Splx group. The two groups were comparable with 
respect to donor and recipient age, sex. HLA-A. B. and DR 
mismatch. etiology of liver disease. UNOS status. cold 
ischemic time. platelet count. and immunosuppressive reg-
imen (Tables 1 and 2). Although there were more positive 
Iymphocytotoxic cross-matches in the study (Splx) group. 
the difference was not statistically significant (Tables 1 and 
2). The two groups were not comparable with respect to the 
amount of perioperative hlood transfusion. 
Indications for splenectomy included positive lymphocy-
totoxic cross-match. (N = 10). portosystemic shunts [distal 
splenorenal shunt (N = 10). portocaval shunt (N = I)]. 
technical complications (N = 10). and distal pancreatic 
tumor resection (N = 2). In seven patients the reason for 
Splx could not he determined in the retrospective review 
(Table 3). 
The two groups were analyzed with respect to patient and 
graft survival. as well as biopsy-proven acute allograft re-
jection within 30 days of transplantation. 
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TABLE 2. DONOR CHARACTERISTICS 
Splenectomized Nonsplenectomized P 
Age (mean:': SD) 27.1 :!: 11.1 29.2 :!: 13.5 0.371 
Cold ischemia time 
(mean:': SD) 12.9 :!: 6.0 13.4 :!: 5.1 0.607 
HLA-A. B. DR 
Matches 
0 13 (48%) 64 (59""') 0.289 
I 14 (52%) 41 (38%) 
2 0 4 (4%) 
Mismatches 
0 3(11%) 16 (15%) 0.176 
1 17 (67%) 47 (43%) 
2 7 (26%) 46 (42%) 
Statistical Analysis. The results for continuous variables 
are presented as means:':: so and for categorical variables 
as proportions. The standard two-sample t test was used to 
test the difference between group means. while differences 
in proportions were tested using Pearson's chi-square test 
or Fisher's exact test. The Wilcoxon rank-sum test, a non-
parametric equivalent to the standard two-sample t test, was 
used for highly skewed data (eg, amount of blood transfu-
sions and platelet count), The odds ratio was calculated as 
an estimate of the relative risk of acute allograft rejection 
for SpJx patients. An odds ratio> I indicates increased risk, 
while an odds ratio < 1 indicates a protective effect of 
splenectomy. The Mantel-Haenszel procedure (18) was 
used to calculate an adjusted odds ratio based on lympho-
cytotoxic cross-match. A multivariate logistic regression 
model was used to adjust the odds ratio for amount of blood 
transfusions. The 95% confidence intervals were calculated 
using either the test-based procedure of Miettinen or 
Woolfs method (18). 
Patient survival was calculated from the date of OLTx 
until death. and graft survival from the date of OLTx until 
retransplantation or patient death. Survival curves were 
generated using the Kaplan-Meier (product-limit) method 
and were compared using the generalized Wilcoxon 
(Breslow) test. All tests were two-tailed. P < 0.05 was 
considered statistically significant. All analyses were per-
formed using SPSS for Windows software. 
TABLE 3. I:-<D1CATtON FOR SPLENECTOMY AND ASSOCIATED 
MORTALITY AT 30 DA YS 
Mona/iN 
N "i: N (%) P 
Positive Iymphocytotoxlc cross-match 10 26.3 
~egative Iymphocytotoxic 28 T~KT 
cross-malch 
Distal splenorcnal shunt (DSRS) 10 
Portocaval shunt I 
Tt:chnical' H 
Pancreatic tumor 2 
U nidenlltied 7 
Total 38" 
• Cross-match status unknown in two patients. 
t Fisher's exact test. 
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RESULTS 
Patient Survival. With a minimum follow-up of one 
year (median 35. range 12-17 months), the one-year 
patient survival was 60% (24/40) in the Splx group vs 
86% (126/147) in the non-Splx group (P = 0.001), a 
disparity that was already significant at 30 days (P = 
0.001) (Figure I). 
In the Splx group, eight patients died within 30 days 
of OLTx (8/40, 10%) compared to five in the non-Splx 
group (5/147, 3%, P < 0.0001). Four of the eight 
deaths were in patients with a positive cross-match 
(4/10, 40%) and the other four in patients with neg-
ative cross-match (4128, 14%, P = 0.093) (Table 3). 
The one-year mortality based on positive cross-match 
was 60% (6/10) in the Splx group and 22% (5/23) in 
the non-Splx group (P = 0.0037). The one-year mor-
tality based on negative cross-match was 36% (10/28) 
in the Splx group and 12% (15/121) in the non-Splx 
group (P = 0.005). 
Seven of the eight deaths in the Splx group during 
the first month (7/40, 17.5%) as well as 12 of the 16 by 
the end of the first year (12/40, 30%) were due 
primarily to sepsis compared to 4/147 (2.7%, P = 
0.0022) and 17/147 (11.6%, P = 0.0043), in the non-
Splx group, respectively. 
Three of the 40 (7.5%) patients in the Splx group, 
including two cross-match-positive patients, under-
went retransplantation within 30 days of OLTx be-
cause of either primary nonfunction (PNF, N = 1) or 
hepatic artery thrombosis (HAT, N = 2). One more 
patient was retransplanted after 30 days, for a total 
incidence of 10%. Two (50%) of the four attempts 
succeeded. Fourteen (9.5%) patients in the non-Splx 
group also underwent retransplantation, including 
three with a positive cross-match liver. Eight (57%) 
were successful. 
Graft Survival. With the equivalent rate of success-
ful retransplantation. the graft survival curves of the 
Splx and non-Splx groups were both 5% lower than 
patient survival, and similar at all time points. Graft 
survival for Splx at one month was 78% vs 93% for 
non-Splx (P == 0.004), and at one year was 55% vs 
SO%. respectively (P == 0.001). 
Multivariate Analysis. Using a multivariate lo-
gistic regression analysis. Splx patients had a higher 
risk of one year mortality (odds ratio == 3.1, P = 
0.042) even after adjusting for selected baseline 
recipient and donor characteristics. However, this 
multivariate analysis did not reveal a significant 
association between splenectomy and graft failure 
at one year. 
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Fig 1. Orthotopic liver transplantation between January 1987 and October 1991. Kaplan-
Meier patient survival. Graft survival in both cohorts was 5% lower (the retransplantation 
factor) but otherwise was essentially identical. 
Rejection. The incidence of acute allograft rejec-
tion one month following OLTx was significantly 
lower in the Splx group (20/40, 50% ) compared to the 
non-Splx group (108/147, 74%, P = 0.005), an advan-
tage seen with and without a positive Iymphocytotoxic 
cross-match (Table 4). 
not affected by the difference in the total amount of 
blood transfusions (Table 5). 
DISCUSSION 
The Splx patients received significantly more units 
of blood transfusion within one month of OLTx than 
non-Splx patients (Table 1); however. in a multivari-
ate logistic regression model. the rejection rate was 
The contribution of the spleen as part of the im-
mune response to the transplanted graft is not clearly 
known (6,19-22). The spleen is not only the principle 
site of antibody synthesis (6, 9, 23). including specific 
alloantibodies (22. 24-26), but also is a source of 
TABLE 4. INCIDENCE OF ACUTE REJECTION ONE MONTH AFrER LIVER TRANSPLANTATION' 
Splenectomized Nonsplenectomized Odds ratio P 
One month 20/40 (50.0%) 108/147 (73.5%) 0.361 0.005 
By Iymphocytotoxic cross-matcht 
Positive 4/ IO (4(1.0% ) 19/23 (82.6':;-) 0.140 lKMPR~ 
Negative 15/28 (53.6%) 88/121 (72.7':;) 0.433 0.(148 
"Test for homogeneity of the odds ratio: P = 0.263: Mantcl-Haenszel estimator of the common odds 
ratio = 0.340: 95 r i confidence interval = 0.161-0.715. 
t Cross-match status unknown In five patients: two Splx. three cuntrols. 
t Fisher's exact test. 
TABLE 5. ESTIMATED RtSK 01 ACUTE REJECTION FOR pfDtKbkbEIqEF~ffwba PATIENTS ADJUSTED FOR A~1Mlfkq OF BLOOD 
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SPLENECTOMY AND LIVER TRANSPLANTATION 
specific alloreactive host lymphocytes (23). It has 
been suggested that transient posttransplant migra-
tion of dendritic cells from the transplanted graft to 
the spleen may be responsible for initiation of graft 
rejection (20). On the contrary the spleen may playa 
major role in prolongation of graft survival in differ-
ent species (19, 21, 23, 27-29), perhaps by generation 
of specific suppressor cells (30). 
Starzl et al (1) were first to suggest the role of 
splenectomy in prolongation of allograft survival, as 
four of their five patients treated by thymectomy and 
splenectomy maintained their renal function for al-
most six months. Hume et al (3) suggested that sple-
nectomy, if done prior to or at the time of transplan-
tation, could improve leukocyte count and permit 
administration of large doses of AZA. A report by 
Gleason and Murray (4), also noted the advantage of 
splenectomy but only in living related kidney trans-
plant patients. Two reports in the 1980s also noted 
improved patient and graft survival after splenectomy 
(7, 8). This is in contrast to several reports in the late 
1980s that have cautioned against the routine use of 
splenectomy in the renal transplant population (9, 10, 
14, 16, 31, 32). 
This retrospective study was undertaken because of 
the concern that decisions to perform urgent splenec-
tomy were made only for its historical justification, 
namely, the mitigation of the spleen-dependent anti-
body response (25, 26, 33-35), without attention to its 
hazards. 
Our concern about splenectomy is similar to those 
that have been experienced in renal transplantation. 
A common theme in the earlier studies was that 
splenectomy appeared to reduce the incidence of 
early rejection (4, 7, 8). Similar to the report by 
Megison (36), SpIx patients in our study had a signif-
icantly lower rate of rejection compared to non-Splx 
patients. This difference was still apparent when re-
jection was stratified by positive and negative lympho-
cytotoxic cross-match (Table 3). Patients with positive 
cross-matches may present with a clinical picture of 
antibody-mediated rejection indistinguishable from 
PNF (37); however. in our study none of the retrans-
planted patients for PNF had any histologically doc-
umented acute rejection. 
In our study splenectomy was associated with more 
hlood transfusion. This extra transfusion requirement 
could be due to unexpected injury to the spleen or 
may be the result of preformed lymphocytotoxic an-
tibody, which may lead to excessive elimination of 
platelets and subsequent hemorrhage (38). 
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The most emphasized risk of splenectomy in the 
literature is the increased susceptibility to infection 
and thrombotic complications. However, in our opin-
ion, the most serious hazard of splenectomy in a liver 
recipient is aggravation of an already difficult techni-
cal operation. 
Nevertheless, splenectomy independent of other 
factors, including blood transfusion, has been asso-
ciated with an increased risk of mortality (16), with 
sepsis as the leading cause. Our concern is rein-
forced by the study reported here and emphasizes 
that the price of this extra surgical procedure far 
outweighs any theoretical benefits in OLTx pa-
tients, We conclude that, based on multiple life-
threatening risk factors associated with splenec-
tomy, concomitant splenectomy with OLTx is not 
recommended except in the rare occasion of un-
avoidable splenic injury. 
Instead of splenectomy for patients with a posi-
tive cytotoxic cross-match, we now recommend in-
traoperative treatment with a combination of high-
dose corticosteroids and prostaglandin E l . This 
treatment is thought to ameliorate the diffuse in-
flammatory response that is the basis of hyperacute 
rejection or its subclinical variations (39, 40). Since 
instituting this management policy in 1992 (41), the 
extra hazard of liver transplantation in the case of 
a positive crossmatch (40, 42) has been all but 
eliminated (43). 
SUMMARY 
The single center experience with splenectomy in 
OLTx patients has been reviewed. One thousand four 
hundred sixty-six patients had OLTx over a period of 
five years. Forty of these patients had splenectomy at 
the time of OLTx. These patients were compared to a 
randomly selected group of OLTx patients who did 
not have splenectomy within the same time period. 
The results demonstrate that splx patients are at 
increased risk for mortality, independent of other 
factors, mainly a due to increased sepsis-related com-
plications. 
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